Chief of the Center for Cellular Engineering
Center for Cellular Engineering
David Stroncek, MD is Chief of the Center for Cellular Engineering in the Department of Transfusion Medicine (DTM), Clinical Center, National Institutes of Health (NIH), Bethesda, Maryland. The Center for Cellular Engineering manufactures and develops a wide variety of novel cellular and gene therapies for phase I/II clinical trials including Chimeric Antigen Receptor (CAR) T cells, T cells expressing engineered T cell receptors, dendritic cells, natural killer cells, bone marrow stromal and genetically engineered hematopoietic stem cells. His group also process hematopoietic progenitors and donor lymphocytes to support hematopoietic stem cell transplantation protocols. Dr. Stroncek’s research is focused on investigating new measures of cell and gene therapy quality and potency. Prior to becoming Chief of the Cell Processing Section 10 years ago, he was Chief of the Laboratory Services Section at the Department of Transfusion Medicine. He has a Bachelor’s of Science degree in Chemical Engineering from the University of Minnesota. He completed medical school, an Internal Medicine Internship and Residency and a Hematology and Oncology Fellowship at the University of Minnesota Medical School. Prior to coming to the NIH in 1996 he was Director of the Blood Bank and Cell Processing Laboratory at the University of Minnesota Hospital and Clinics.